Currently out of the existing stock ratings of Brandon Folkes, 190 are a BUY (90.91%), 19 are a HOLD (9.09%).

Brandon Folkes

Work Performance Price Targets & Ratings Chart

Analyst Brandon Folkes, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 31.82% that have a potential upside of 20.92% achieved within 225 days.

Brandon Folkes’s has documented 414 price targets and ratings displayed on 49 stocks. The coverage is on Healthcare, Energy sectors.

Most recent stock forecast was given on MIST, Milestone Pharmaceuticals at 03-Sep-2026.

Wall Street Analyst Brandon Folkes

Analyst best performing recommendations are on ANIP (ANI PHARMACEUTICALS).
The best stock recommendation documented was for ANIP (ANI PHARMACEUTICALS) at 8/7/2025. The price target of $84 was fulfilled within 4 days with a profit of $14.99 (21.72%) receiving and performance score of 54.3.

Average potential price target upside

of $67.83 (73.44%) on VERU (VERU).
of $58.65 (75.91%) on OPTN (OPTINOSE).
of $46.55 (34.84%) on JAZZ (JAZZ PHARMACEUTICALS PLC).

BDSI BioDelivery Sciences International COLL Collegium Pharmaceutical EBS Emergent Biosolutions EGRX Eagle Pharmaceuticals HRTX Heron Therapeuti KIN Kindred Biosciences OPTN OptiNose TRVN Trevena VERU Veru ALKS Alkermes Plc JAZZ Jazz Pharmaceuticals PLC MNKD MannKind Corp IMV IMV OBSV ObsEva SA RDHL Redhill Biopharma Ltd OMER Omeros ACRX AcelRx Pharmaceuticals AMYT Amryt Pharma Holdings Ltd ANIP ANI Pharmaceuticals AXGN Axogen CERS Cerus CHMA Chiasma SPNE SeaSpine Holdings Corp VRAY ViewRay AZYO Aziyo Biologics RANI Rani Therapeutics Holdings RMTI Rockwell Medical SMTI Sanara Medtech ACHV Achieve Life Sciences AMAG AMAG Pharmaceuticals CRMD CorMedix DERM Journey Medical Corp INSY INSYS Therapeutics MNTA Momenta Pharmaceuticals PAHC Phibro Animal Health PYPD PolyPid TRVI Trevi Therapeutics VALN Valneva SE ADR CNTB Connect Biopharma Holdings Ltd ENTA Enanta Pharmaceuticals MIST Milestone Pharmaceuticals CRDL Cardiol Therapeutics XERS Xeris Pharmaceuticals ADIL Adial Pharmaceuticals AM Antero Midstream Partners LP GNFT Genfit INDV Indivior PLC Ordinary Shares SCLX Scilex Holding Company SGMT Sagimet Biosciences Series A Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gregory Fraser (TRUIST)

Hold

$0.41 (7.33%)

4 years 6 months 15 days ago
(25-Feb-2022)

1/4 (25%)

$2.17 (44.83%)

281

David Amsellem (PIPER SANDLER)

Buy Since 09-Jan-2020

$5.6

$0.01 (0.18%)

$5.6

4 years 6 months 25 days ago
(15-Feb-2022)

2/3 (66.67%)

$0.04 (0.72%)

Oren Livnat (HC WAINWRIGHT)

Hold Since 10-Nov-2021

$4.5

$-1.09 (-19.50%)

$4.5

4 years 7 months 19 days ago
(21-Jan-2022)

6/7 (85.71%)

$1.14 (33.93%)

152

Scott Henry (ALLIANCE GLOBAL PARTNERS)

Buy Since 14-Aug-2018

$6.25

$0.66 (11.81%)

$4.5

5 years 4 months 3 days ago
(06-May-2021)

2/3 (66.67%)

$3.07 (96.54%)

228

Matthew Kaplan (COWEN)

Buy Since 14-Oct-2015

$2.41 (43.11%)

$21

6 years 9 months 27 days ago
(13-Nov-2019)

0/2 (0%)

$2 (33.33%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Brandon Folkes most bullish on?

Potential upside of $36.64 has been obtained for COLL (COLLEGIUM PHARMACEUTICAL)

Which stock is Brandon Folkes most reserved on?

Potential downside of $3.51 has been obtained for ACHV (ACHIEVE LIFE SCIENCES)

What Year was the first public recommendation made by Brandon Folkes?

On 2016